Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Provectus and Sinopharm Facing MOU Deadline for Partnership

publication date: May 8, 2015
Provectus, a Tennessee clinical-stage biopharma, reiterated that the company remains committed to finding a China partner for its lead molecule, PV-10, a cancer treatment. In August 2014, Provectus signed a MOU with Sinopharm, a state-owned company, for China rights to PV-10. That agreement has been extended past its original 3-month limit, but it expires again next week, on May 16. Provectus said it hopes to sign a deal with Sinopharm prior to the date. More details....

Stock Symbol: (NYSE: PVCT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital